Loading organizations...

§ Private Profile · 1155 Island Avenue, Suite 100, San Diego, CA 92101, USA
Novoron Bioscience is a technology company.
Novoron Bioscience develops novel therapeutic approaches focused on lipoprotein-receptor drug development to address neurological damage and disease within the central nervous system. The company leverages its unique expertise and proprietary tools to target specific pathways within the low-density lipoprotein receptor family, particularly LRP1, to modulate disease-relevant physiology while preserving essential homeostatic functions. This technical approach aims to block the spread of harmful proteins in proteinopathies and enhance the regenerative capacity following spinal cord injuries.
The company was co-founded in 2014 by Travis Stiles, PhD, who serves as CEO, and Shawn Gahr, MIA, who is the COO. Their foundational insight stemmed from recognizing the untapped therapeutic potential within LDL receptor biology, a target class that historically presented significant challenges for drug development. Dr. Stiles brings a scientific background to the leadership, complemented by Gahr's operational and strategic expertise, forming a team dedicated to advancing this complex area of neuroscience.
Novoron Bioscience primarily serves patients suffering from debilitating neurological conditions, including those associated with proteinopathies and spinal cord injuries. The company’s long-term vision is to restore independence and significantly improve the quality of life for these patients. It focuses on developing innovative, first-in-class therapies by meticulously exploring every option, including multi-modality discovery and optimized drug delivery, to deliver the best possible treatments.
Novoron Bioscience has raised $13.7M across 3 funding rounds.
Novoron Bioscience has raised $13.7M in total across 3 funding rounds.
Novoron Bioscience has raised $13.7M across 3 funding rounds. Most recently, it raised $10.0M Seed in December 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2022 | $10M Seed | — | Accomplice VC, Evolution Equity Partners, Karim Faris, Nokia Growth Partners, TWO Bear Capital | Announced |
| Nov 1, 2021 | $3M Seed | TWO Bear Capital | Accomplice VC, Evolution Equity Partners, Karim Faris, Nokia Growth Partners | Announced |
| Dec 22, 2015 | $680K Grant | National Institutes OF Health | — | Announced |
Novoron Bioscience has raised $13.7M in total across 3 funding rounds.
Novoron Bioscience's investors include Accomplice VC, Evolution Equity Partners, Karim Faris, Nokia Growth Partners, Two Bear Capital, National Institutes of Health.
Novoron Bioscience is a San Diego–based biotech company developing first‑in‑class therapeutics that exploit lipoprotein/LDL‑receptor biology to promote neuroregeneration and block propagation of pathological protein aggregates in central nervous system (CNS) diseases such as spinal cord injury, multiple sclerosis, and tauopathies including Alzheimer’s disease[2][1].
High‑Level Overview
For the product/company view:
Origin Story
Core Differentiators
Role in the Broader Tech/Biotech Landscape
Quick Take & Future Outlook
If you’d like, I can: